Image

MAgna GraecIa Evaluation of Comorbidities in Patients With Heart Failure STUDY

Recruiting
18 - 80 years of age
Both
Phase N/A

Powered by AI

Overview

The MAGIC-HF STUDY project (MAgna GraecIa evaluation of Comorbidities in patients with Heart Failure STUDY), is an observational prevalence and incidence study focusing on the role that risk factors, various comorbidities, and their treatment may have on CV and non-CV outcomes in patients with all forms of HF. It also aim to assess whether comorbidities and their treatment may be predictors of response to pharmacological and non-drug treatment of HF.

Description

Adult subjects with all forms of HF (HFrEF, HFmrEf, HEpEF) with at least one comorbidity who are referred to the Heart Failure Outpatient Clinic of the AOU "Mater Domini" Geriatrics Unit in Catanzaro will be recruited.

Initially, patients will be evaluated at baseline and followed-up for a minimum of six-month.

All patients will be subjected to clinical, instrumental and laboratory examinations, including medical history data collection and complete anthropometric assessment . Plasma and serum samples will be collected at recruitment and at the six-months follow-up visit. Stool samples will also be obtained and stored at -80C for the omics studies.

Eligibility

Inclusion Criteria:

  • Informed Consent obtained before performing any procedure
  • Age>18 years old
  • Confirmed diagnosis of HFrEF, HFmrEF, HFpEF with clinical stability for at least 4 weeks
  • Presence of at least one of the following comorbidities:
  • Atrial fibrillation
  • Peripheral arteriopathy
  • Hypertension
  • Chronic ischemic heart disease
  • Diabetes mellitus type 2 or insulin resistance
  • Hepatopathy
  • Obesity
  • Cancer
  • Sleep apnea syndrome
  • Chronic kidney disease
  • Iron deficiency
  • Cognitive Decline or Depression
  • Sarcopenia
  • Dysthyroidisms
  • Hypovitaminosis D
  • Hyperuricemia

Exclusion Criteria:

  • Liver cirrhosis Child-Pugh C
  • Severe chronic renal failure defined by an estimated glomerular filtration rate (eGFR) value < 15 ml/min/1.73 m2 according to CKD-EPI
  • Suspected alcohol or drug abuse
  • Pregnancy or breast feeding

Study details

Heart Failure

NCT05915364

University of Catanzaro

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.